| Title |
Valbenazine: First Global Approval
|
|---|---|
| Published in |
Drugs, June 2017
|
| DOI | 10.1007/s40265-017-0770-9 |
| Pubmed ID | |
| Authors |
Esther S. Kim |
| Abstract |
Valbenazine (Ingrezza™) is an orally bioavailable, selective, vesicular monoamine transporter 2 (VMAT2) inhibitor being developed by Neurocrine Biosciences for the treatment of various central nervous system disorders. Valbenazine has been approved in the USA for the treatment of adults with tardive dyskinesia (TD), is at various stages of development in other countries for TD and is in phase 2 development in the USA for Tourette syndrome. This article summarizes the milestones in the development of valbenazine leading to its first global approval in the USA for the treatment of adults with TD. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Costa Rica | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 15 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 3 | 20% |
| Student > Master | 2 | 13% |
| Student > Bachelor | 1 | 7% |
| Student > Doctoral Student | 1 | 7% |
| Researcher | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 6 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 13% |
| Nursing and Health Professions | 2 | 13% |
| Biochemistry, Genetics and Molecular Biology | 1 | 7% |
| Engineering | 1 | 7% |
| Other | 0 | 0% |
| Unknown | 6 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 March 2021.
All research outputs
#6,102,286
of 22,988,380 outputs
Outputs from Drugs
#1,050
of 3,285 outputs
Outputs of similar age
#97,443
of 317,468 outputs
Outputs of similar age from Drugs
#11
of 37 outputs
Altmetric has tracked 22,988,380 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 3,285 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,468 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.